PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic Journal

Irish Journal of Medical Science

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

Irish Journal of Medical Science has 1 tracked paper indexed in Blossom (2021) from 11 authors, most often covering Psilocybin, across Anxiety Disorders, Bipolar Disorder and Depressive Disorders.

Published Papers

Open Accessindividual

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

A survey of 99 mental health service users found that most supported further research into psilocybin (72%) and its medical use (59%), with 55% saying they would accept it if recommended by a doctor; favourable attitudes were more common in younger people, those with prior psychedelic experience, and non‑religious individuals. Nonetheless, significant reservations remained—around one fifth viewed psychedelics as addictive or unsafe and concerns included adverse effects, illegality and relapse risk, while a small minority with psychosis/bipolar still considered it useful despite potential harm.

Published
June 15, 2021
Journal
Irish Journal of Medical Science
Authors
Corrigan, K., Haran, M., Mccandliss, C., Mcmanus, R., Cle, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O'keane, V., Kelly, J. R.

Quick Facts

Papers Indexed
1
h-Index
46
Open Access
No
Publisher
Springer Nature
Country
United Kingdom
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.